Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mass Balance and Absolute Bioavailability of AZD4604 in Healthy Volunteers
NCT06157255Phase 1Completed
- Sponsor
- AstraZeneca
- Start
- Feb 2024
- Primary completion
- May 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of londamocitinib in asthma, sponsored by AstraZeneca. Primary endpoints: Amount of AZD4604 excreted, Fraction of dose excreted and 10 more. Started Feb 2024; status: completed.
02
Drugs
londamocitinib
03
Conditions
asthma
Beyond the preview
Go deeper on NCT06157255.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06157255.